The FDA has posted Otsuka ICU Medical's recall of a saline lot that may contain potassium chloride bags, and federal records show it is the third potassium chloride packaging problem in the company's IV solutions line in 19 months. The two earlier recalls, announced in February and October 2025, involved potassium bags whose outer wraps listed the wrong dose.
For families of hospitalized patients, the pattern raises a different question than the recall alone. The affected lot is limited, and no injuries have been reported, but all three cases point to the same weak spot: an outer wrap that says one thing while the bag inside holds another.
That places extra weight on the final bedside check. In each case, the correct information was printed on the inner bag, which clinicians see clearly only after the overwrap comes off.
One Product Code, Three Recalls
The current recall, announced Sept. 17 and posted by the FDA on Sept. 21, covers 0.9% Sodium Chloride Injection, USP, 100 mL, lot 1042188 (NDC 0990-7984-23), which expires Oct. 31, 2027. Some bags in that saline overwrap may actually be Potassium Chloride Injection 10 mEq, lot 1035181. A customer complaint revealed the problem. The lot was distributed in the United States from Dec. 30, 2025, through June 22, 2026.
On Feb. 13, 2025, ICU Medical recalled a lot of 20 mEq potassium chloride bags whose overwraps said 10 mEq, according to the FDA-posted notice for that recall. On Oct. 31, 2025, Otsuka ICU Medical announced a nearly identical recall of a different 20 mEq lot, again with a 10 mEq overwrap. Both earlier notices attributed the error to a manufacturing issue.
Each recall involves the same 10 mEq product, NDC 0990-7074-26. In the first two, that product's 10 mEq label appeared on the wrap around a stronger bag. In the latest, the 10 mEq bag itself turned up inside a saline wrap, a different failure with the same product at its center.
The product line changed hands between the recalls. ICU Medical moved its IV solutions business, based in Austin, Texas, into the Otsuka ICU Medical joint venture in May 2025, according to ICU Medical's announcement. The company has not said whether the three incidents share a cause, and none of the notices report patient harm.
The Label Inside the Wrap Is the Last Line of Defense
The latest notice says the misplaced potassium bag carries its own label clearly identifying it as potassium chloride. That printed label on the inner bag is where a mix-up can still be caught before it reaches a patient.
Hospitals have spent decades building guardrails around intravenous potassium. The Joint Commission does not permit concentrated potassium injection to be stored in patient care areas, according to the International Medication Safety Network. The labeling for this ready-to-use product describes it as highly concentrated, warns against rapid infusion, and calls for continuous cardiac monitoring, according to label text reproduced by Drugs.com.
A mix-up hidden inside saline packaging can slip past some of those guardrails, because saline is stocked widely and handled constantly. In a 2011 commentary in Pharmacy and Therapeutics, Matthew Grissinger of the Institute for Safe Medication Practices urged clinicians not to grow complacent about the risks of intravenous potassium, a high-alert medication. His warning predates these recalls, but it describes the same vulnerability.
MedicalDaily's initial report on the saline recall laid out the lot details and the return instructions sent to hospitals. The latest records do not change those instructions.
Patients Most Exposed to a Potassium Error
The company's risk statement says inadvertent injection of highly concentrated potassium chloride carries "a reasonable probability" of adverse events and potentially fatal outcomes. It lists premature infants, patients on long-term intravenous nutrition, people with a history of heart rhythm problems, patients with chronic kidney insufficiency or acute kidney failure, and those taking potassium-sparing diuretics as most at risk.
Possible effects include muscle weakness, ascending paralysis, confusion, low blood pressure, irregular heart rhythms, and cardiac arrest. None has been reported with this lot.
Those risk groups describe many families' daily realities. They include parents with a baby in a neonatal intensive care unit, adults with kidney failure, and older relatives with heart rhythm disorders. For those households, the question is less about one lot number and more about whether the checks around every IV bag are working.
Questions Families Can Ask and the FDA's Next Step
Patients cannot inspect hospital IV stock, and no one needs to refuse IV fluids because of this recall. Families can reasonably ask a nurse what a bag contains before it is hung and whether the unit scans IV bags at the bedside. Those are routine questions, and they reflect safeguards many hospitals already use.
A patient receiving IV fluids who develops new muscle weakness, a racing or irregular heartbeat, or sudden confusion should alert the care team immediately. No one should change a prescribed treatment based on this report without talking with a clinician.
The FDA had not assigned a recall classification as of Sept. 22. The agency typically classifies recalls after reviewing them and lists them in its weekly enforcement reports. That classification, and any explanation of a root cause across the three incidents, would be the next meaningful developments. MedicalDaily will also report any adverse events or any expansion of the affected lot.
Key Questions Answered
What is new since the recall was first announced?
The FDA posted the recall notice on Sept. 21. Federal records also show two earlier 2025 recalls in the same IV product line in which potassium chloride bags carried overwraps listing the wrong dose.
What is being recalled now?
One lot of 0.9% Sodium Chloride Injection, USP, 100 mL, lot 1042188, NDC 0990-7984-23. Some bags in saline overwraps may contain Potassium Chloride Injection 10 mEq.
Has anyone been harmed?
The company says it has received no reports of adverse events. The two earlier recalls also reported no adverse events at the time they were announced.
Are the three recalls connected?
The company has not said whether they share a cause. All three involve the same 10 mEq potassium chloride product.
Who faces the greatest risk from a potassium mix-up?
Premature infants, patients on long-term IV nutrition, people with heart rhythm problems or kidney failure, and those taking potassium-sparing diuretics.
What can families of hospitalized patients do?
They can ask what an IV bag contains and whether the unit scans bags at the bedside. New muscle weakness, an irregular heartbeat, or sudden confusion should be reported to the care team right away.
